blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3638298

EP3638298 - PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND FORMULATIONS THEREOF FOR TREATMENT OF SYNUCLEINOPATHIES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  11.04.2024
Database last updated on 30.10.2024
FormerRequest for examination was made
Status updated on  20.03.2020
FormerThe international publication has been made
Status updated on  22.12.2018
Most recent event   Tooltip07.10.2024New entry: Reply to examination report 
Applicant(s)For all designated states
United Neuroscience
1 Cayman Financial Centre
36A Dr. Roy's Drive
P.O. Box 2510
Grand Cayman KY1-1104 / KY
[2020/17]
Inventor(s)01 / WANG, Chang Yi
47 Snake Hill Road
Cold Spring Harbor, New York 11724 / US
 [2020/17]
Representative(s)Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2020/17]Weickmann & Weickmann PartmbB
Postfach 860 820
81635 München / DE
Application number, filing date18816482.615.06.2018
[2020/17]
WO2018US37938
Priority number, dateUS201762521287P16.06.2017         Original published format: US 201762521287 P
[2020/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018232369
Date:20.12.2018
Language:EN
[2018/51]
Type: A1 Application with search report 
No.:EP3638298
Date:22.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 20.12.2018 takes the place of the publication of the European patent application.
[2020/17]
Search report(s)International search report - published on:US20.12.2018
(Supplementary) European search report - dispatched on:EP01.04.2021
ClassificationIPC:A61K39/00, A61P25/28, C07K14/00, C07K16/18, C07K19/00, C07K14/47
[2021/18]
CPC:
C07K14/47 (EP,KR); A61K39/0007 (EP,KR,US); A61P25/28 (EP,KR);
C07K16/18 (EP,KR); C07K19/00 (EP); G01N33/563 (KR);
A61K2039/55505 (EP,KR,US); A61K2039/55561 (EP,KR,US); A61K2039/55566 (EP,KR,US);
A61K2039/6037 (EP,KR,US); A61K2039/6068 (EP,KR,US); A61K2039/6075 (EP,KR,US);
C07K2317/34 (EP,KR); C07K2317/92 (EP,KR) (-)
Former IPC [2020/17]A61K39/00, A61P25/28, C07K14/00, C07K16/18, C07K19/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/17]
TitleGerman:PEPTIDIMMUNOGENE AUS DEM C-TERMINALEN ENDE VON ALPHA-SYNUCLEIN-PROTEIN UND FORMULIERUNGEN DAVON ZUR BEHANDLUNG VON SYNUCLEINOPATHIEN[2020/17]
English:PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND FORMULATIONS THEREOF FOR TREATMENT OF SYNUCLEINOPATHIES[2020/17]
French:IMMUNOGÈNES PEPTIDIQUES PROVENANT DE L'EXTRÉMITÉ C-TERMINALE D'UNE PROTÉINE, L'ALPHA-SYNUCLÉINE, ET COMPOSITIONS EN CONTENANT POUR LE TRAITEMENT DES SYNUCLÉINOPATHIES[2020/17]
Entry into regional phase14.01.2020National basic fee paid 
14.01.2020Search fee paid 
14.01.2020Designation fee(s) paid 
14.01.2020Examination fee paid 
Examination procedure14.01.2020Examination requested  [2020/17]
27.10.2021Amendment by applicant (claims and/or description)
10.04.2024Despatch of a communication from the examining division (Time limit: M06)
07.10.2024Reply to a communication from the examining division
Fees paidRenewal fee
14.01.2020Renewal fee patent year 03
24.09.2021Renewal fee patent year 04
27.06.2022Renewal fee patent year 05
27.06.2023Renewal fee patent year 06
27.06.2024Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
30.06.202104   M06   Fee paid on   24.09.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]EP2272539  (ELAN PHARM INC [US]) [X] 10,11 * Par.10, 15, 16, 18, 91 *;
 [X]EP2370466  (PANIMA PHARMACEUTICALS AG [CH], et al) [X] 10,11,15 * p.1 l.5-13, p.3 l.15-21, p.28 l.5-10, p.29 l.18-19, p.29 l.24-26 *;
 [Y]US2016068581  (WANG CHANG YI [US]) [Y] 1-9,12-14* par.13,78,98 *;
    [ ] - "Sequence 6 from Patent EP2272539.", EPO Proteins, (20110426), Database accession no. JA249443, URL: EBI [ ] * sequence . *
 [XY]  - MASLIAH E ET AL, "Effects of alpha-synuclein immunization in a mouse model of Parkinsons disease", NEURON, CELL PRESS, US, (20050616), vol. 46, no. 6, doi:10.1016/J.NEURON.2005.05.010, ISSN 0896-6273, pages 857 - 868, XP008091682 [X] 10,11 * p.852 col.2 par.1, p.857 col.2 par.3, p.857 col.2 par.4 - p.858 col.1 par.1, p.864 col.2 par.1, p.865 col.1 par.1 * [Y] 1-9,12-14

DOI:   http://dx.doi.org/10.1016/j.neuron.2005.05.010
 [XY]  - MARKUS MANDLER ET AL, "Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials", ACTA NEUROPATHOLOGICA, (20140214), vol. 127, no. 6, doi:10.1007/s00401-014-1256-4, ISSN 0001-6322, pages 861 - 879, XP055203363 [X] 10,11 * p.862 col.1 par.3,4, Fig.1 * [Y] 1-9,12-14

DOI:   http://dx.doi.org/10.1007/s00401-014-1256-4
International search[A]US2011070255  (WANG CHANG YI [US]) [A] 1-4, 6-11, 13-20, 22-25* entire document *;
 [Y]WO2014031697  (INST OF MOLECULAR MEDICINE [US]) [Y] 1-4, 6, 7, 10, 11, 13, 22-24 * entire document *;
 [Y]US2015139937  (GENDELMAN HOWARD E [US], et al) [Y] 1-4, 6, 7, 10, 11, 13, 22-24 * entire document *;
 [A]WO2015179867  (UNIV SOUTH FLORIDA [US]) [A] 1-4, 6-11, 13-20, 22-25 * entire document *;
 [Y]US2016068581  (WANG CHANG YI [US]) [Y] 1-4, 6, 7, 10, 11, 13, 22-24 * entire document *;
 [A]  - WANG et al., "UB-311, a novel UBITh amyloid b peptide vaccine for mild Alzheimer's disease", Alzheimer's & Dementia Translational - Research & Clinical Interventions, (20170414), vol. 3, no. 2, pages 262 - 272, XP055555535 [A] 1-4, 6-11, 13-20, 22-25 * entire document *

DOI:   http://dx.doi.org/10.1016/j.trci.2017.03.005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.